NVS and NOVN:SW Related Headlines
Go Back- Novartis (NOVN:SW) (NVS) PT Lowered to CHF92 at Berenberg
- Novartis (NOVN:SW) (NVS) PT Raised to CHF135 at JPMorgan
- Novartis (NOVN:SW) (NVS) PT Raised to CHF131 at CLSA
- Novartis (NOVN:SW) (NVS) PT Lowered to CHF132 at Citi
- Citi Starts Novartis (NOVN:SW) (NVS) at Buy
- Novartis (NOVN:SW) (NVS) PT Raised to CHF116 at UBS
- Novartis (NOVN:SW) (NVS) PT Raised to CHF125 at Deutsche Bank
- Barclays Upgrades Novartis (NOVN:SW) (NVS) to Equalweight
- JPMorgan Upgrades Novartis (NOVN:SW) (NVS) to Overweight
- Morgan Stanley Upgrades Novartis (NOVN:SW) (NVS) to Overweight
- Erste Group Upgrades Novartis (NOVN:SW) (NVS) to Buy
- BofA Securities Upgrades Novartis (NOVN:SW) (NVS) to Buy
- Novartis (NOVN:SW) (NVS) PT Raised to CHF92 at Berenberg
- CLSA Starts Novartis (NOVN:SW) (NVS) at Outperform (2)
- Morgan Stanley Upgrades Novartis (NOVN:SW) (NVS) to Overweight
- Barclays Reiterates Underweight Rating on Novartis (NOVN:SW) (NVS)
- UBS Reiterates Neutral Rating on Novartis (NOVN:SW) (NVS)
- Deutsche Bank Reiterates Buy Rating on Novartis (NOVN:SW) (NVS)
- Novartis (NOVN:SW) (NVS) PT Raised to CHF108 at Morgan Stanley
- Deutsche Bank Reiterates Buy Rating on Novartis (NOVN:SW) (NVS)
- Deutsche Bank Reiterates Buy Rating on Novartis (NOVN:SW) (NVS)
- Goldman Sachs Downgrades Novartis (NOVN:SW) (NVS) to Sell
- Novartis (NOVN:SW) (NVS) PT Raised to CHF105 at Morgan Stanley
- Novartis (NOVN:SW) (NVS) PT Raised to CHF120 at Deutsche Bank
- Novartis (NOVN:SW) (NVS) PT Lowered to CHF95 at UBS
- Deutsche Bank Reiterates Buy Rating on Novartis (NOVN:SW) (NVS)
- Deutsche Bank Reiterates Buy Rating on Novartis (NOVN:SW) (NVS)

